Research programme: anti-osteopontin polyclonal antibody - The Feinstein Institute for Medical Research

Drug Profile

Research programme: anti-osteopontin polyclonal antibody - The Feinstein Institute for Medical Research

Alternative Names: anti-OPN Ab - The Feinstein Institute for Medical Research

Latest Information Update: 28 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Feinstein Institute for Medical Research
  • Class Glycoproteins; Polyclonal antibodies
  • Mechanism of Action Osteopontin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Sepsis

Most Recent Events

  • 26 Feb 2015 Preclinical trials in Sepsis in USA (IV-injection)
  • 26 Feb 2015 Pharmacodynamics data from preclinical studies in Sepsis released by The Feinstein Institute for Medical Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top